Immunotherapy Special Issue

An Important Research Goal: Make Immunotherapy Reliably Effective for More Patients Who Have Cancer

June 26, 2018

Editor's Page

We've known for over a century about rare patients who experience spontaneous regressions of cancer. We don’t have absolute proof, but, presumably, this occurs because their immune systems are able to rally and fight the disease.

With Checkpoint Inhibitors Here to Stay, Patient Selection Has Become a Science of its Own

June 26, 2018

From the Chairman

Checkpoint inhibitors — immunotherapy drugs that are improving the treatment landscape for many patients across the spectrum of cancers — are relatively new. The science involved in finding and treating the patients most likely to respond to these drugs — without overlooking any or treating those who won’t benefit — is even newer.

x